15-05-2025
J.P. Morgan Remains a Buy on Septerna, Inc. (SEPN)
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Septerna, Inc. (SEPN – Research Report) yesterday. The company's shares closed yesterday at $10.16.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Joseph covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Bluebird Bio, and Rocket Pharmaceuticals. According to TipRanks, Joseph has an average return of 3.0% and a 46.12% success rate on recommended stocks.
Currently, the analyst consensus on Septerna, Inc. is a Moderate Buy with an average price target of $19.00.
Based on Septerna, Inc.'s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $212 thousand and a GAAP net loss of $20.67 million. In comparison, last year the company earned a revenue of $118 thousand and had a net profit of $34.89 million
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SEPN in relation to earlier this year. Most recently, in March 2025, Ezekowitz Alan, a Director at SEPN bought 13,319.00 shares for a total of $92,167.48.
